Vir biotechnology inc stock.

Nov 6, 2023 · Portland. 5100 S. Macadam Avenue Suite 575 Portland, OR 97239. St. Louis. 4240 Duncan Avenue Suite 300 St. Louis, MO 63110$-4.49 Market Cap $1.30 B Shares Outstanding 134.52 M Public Float 87.48 M Yield VIR is not currently paying a regular dividend. Latest Dividend N/A Ex-Dividend Date N/A Short Interest (10/31/23)...Aug 4, 2020 · Common Stock, $0.0001 par value : VIR : ... Vir Biotechnology, Inc. (the “Company”), GlaxoSmithKline Trading Services Limited (“GSKTSL”), and WuXi Biologics (Hong Kong) Limited (“WuXi”) entered into an Assignment and Novation Agreement effective as of July 29, 2020 (“WuXi Assignment Agreement”) pursuant to which the Company ...VIR - Vir Biotechnology Inc - Stock screener for investors and traders, financial visualizations.Nov 24, 2023 · The stock of Vir Biotechnology Inc (VIR) has gone up by 1.65% for the week, with a 15.63% rise in the past month and a -23.42% drop in the past quarter. The volatility ratio for the week is 3.44%, and the volatility levels for the past 30 days are 5.31% for VIR. The simple moving […]

Sep 13, 2023 · What is Vir Biotechnology Inc’s stock style? VIR’s stock style is Small Growth. Style is an investment factor that has a meaningful impact on investment risk and returns.

Feb 23, 2023 · Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $3.92 per share a year ago ...Nov 27, 2023 · The firm owned 156,478 shares of the company’s stock after selling 142,619 shares during the period. Citigroup Inc. owned 0.12% of Vir Biotechnology worth $3,838,000 at the end of the most ...

Vir Biotechnology Inc’s stock is NA in 2023, NA in the previous five trading days and down 63.15% in the past year. Currently, Vir Biotechnology Inc does not have a price-earnings ratio. Vir Biotechnology Inc’s trailing 12-month revenue is $118.8 million with a -505.6% net profit margin.Oct 16, 2023 · The low in the last 52 weeks of Vir Biotechnology stock was 7.72. According to the current price, Vir Biotechnology is 130.05% away from the 52-week low. What was the 52-week high for Vir ... Feb 25, 2021 · Vir Biotechnology, Inc. (the “Company”), pursuant to its 2019 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock …Noble Financial analyst Robert LeBoyer reiterated a Buy rating on MAIA Biotechnology, Inc. (MAIA – Research Report) today and set a price ... Noble Financial analyst Robert LeBoyer reiterated a Buy rating on MAIA Biotechnology, Inc. (...Nov 6, 2023 · Guided by science, we relentlessly build on our immunologic expertise and technologies in pursuit of transformative medicines for infectious diseases and other serious conditions. Our innovations stem from courage and bold ideas. We approach each day with a sense of optimism and humility, recognizing that our strength resides in the diversity ...

Nov 13, 2023 · SAN FRANCISCO, November 08, 2023--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it ranked first for the second year in a row on the 2023 Deloitte Technology Fast 500™, a list of the ...

VIR has a greater upside potential (average analyst target price relative to current price) than 3950.84% of stocks in the mid market cap category. To contextualize these metrics, consider that out of Pharmaceutical Products stocks, VIR BIOTECHNOLOGY INC's average analyst price target is greater than 3022.14% of them.

Fiscal Q3 2023 ended 9/30/23. Reported on 11/2/23. Get the latest Vir Biotechnology Inc (VIR) real-time quote, historical performance, charts, and other financial information to help you... Contact. Investors. The Investor Relations website contains information about Vir's business for stockholders, potential investors, and financial analysts.Nov 2, 2023 · IR Contact. Vir Biotechnology, Inc. 1800 Owens St., Suite 900 San Francisco, CA 94158. contact us by phone 415-906-4324 [email protected]. Follow us. opens in a new windowNoble Financial analyst Robert LeBoyer reiterated a Buy rating on MAIA Biotechnology, Inc. (MAIA – Research Report) today and set a price ... Noble Financial analyst Robert LeBoyer reiterated a Buy rating on MAIA Biotechnology, Inc. (...Oct 18, 2022 · Vir Biotechnology, Inc. is a commercial-stage immunology company, which is focused on combining immunologic insights with technologies to treat and prevent serious infectious diseases. The Company's pipeline consists of sotrovimab and other product candidates targeting hepatitis B virus (HBV), hepatitis D virus (HDV), influenza A virus, …

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -19.83% and 71.78%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?Stock Info. Stock Quote; Analyst Coverage; Financials. Quarterly Reports; SEC Filings; Governance. Governance Documents; Committee Composition; …Find the latest Vir Biotechnology, Inc. (VIR) stock quote, history, news and other vital information to help you with your stock trading and investing.Nov 24, 2023 · Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference Oct 12 2023; Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023 Oct 11 2023; Vir Biotechnology to Provide Business …Apr 5, 2023 · Presently, the company commands a market cap of just over $2 billion. One of the larger biotech stocks to buy on this list, ABCL features an average trading volume of 1.73 million. Since the Jan ...

Nov 24, 2023 · Vir Biotechnology Inc’s stock is NA in 2023, NA in the previous five trading days and down 63.15% in the past year. Currently, Vir Biotechnology Inc does not have a price-earnings ratio. Vir Biotechnology Inc’s trailing 12-month revenue is $118.8 million with a -505.6% net profit margin. Nov 9, 2023 · Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious ...

Vir Biotechnology Inc stock has a Growth Score of 48, Estimate Revisions Score of 25 and Quality Score of 64. Comparing CureVac BV and Vir Biotechnology Inc’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not.Vir Biotechnology Inc stock has a Value Score of 36, Growth Score of 47 and Estimate Revisions Score of 30. Comparing Immunocore Holdings PLC - ADR and Vir Biotechnology Inc’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not.Nov 30, 2023 · The stock of Vir Biotechnology Inc (VIR) has seen a 4.14% increase in the past week, with a 21.99% gain in the past month, and a -23.88% decrease in the past quarter. The volatility ratio for the week is 3.65%, and the volatility levels for the past 30 days are at 5.18% for VIR. The […] Nov 24, 2023 · Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; …Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 ...Nov 3, 2023 · Vir Biotechnology, Inc. (in Europe, Humabs BioMed, https://bit.ly/46lQGN2) is an immunology company focused on powering the immune system to address unmet patient needs in infectious disease and ...

Jan 13, 2022 · PHILADELPHIA and SAN FRANCISCO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the submission of an application to the US Food and Drug Administration (FDA) requesting an amendment to the Emergency Use Authorization …

Nov 4, 2021 · Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company has assembled two technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations …

Get a real-time Vir Biotechnology, Inc. (VIR) stock price quote with breaking news, financials, statistics, charts and more.Stock Price Target. High, $95.00. Low, $12.00. Average, $29.75. Current Price, $9.82. VIR will report FY 2023 earnings on 02/23/2023. Yearly Estimates. 20222023 ...Stock Price Target. High, $95.00. Low, $12.00. Average, $29.75. Current Price, $9.82. VIR will report FY 2023 earnings on 02/23/2023. Yearly Estimates. 20222023 ...Jul 20, 2023 · Vir Biotechnology Inc. (VIR) said Thursday a mid-stage trial of a treatment for symptomatic flu failed to meet its main goals, sending the stock down 40% premarket.Sep 8, 2023 · Overall, Vir Biotechnology Inc stock has a Value Score of 48, Growth Score of 48 and Quality Score of 43. Alkermes Plc stock has a Value Score of 12, Growth Score of 62 and Quality Score of 78. Comparing Vir Biotechnology Inc and Alkermes Plc’s grades, scores and metrics can act as a solid basis to determine whether they may be a good ... Jan 13, 2022 · PHILADELPHIA and SAN FRANCISCO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the submission of an application to the US Food and Drug Administration (FDA) requesting an amendment to the Emergency Use Authorization …Discover historical prices for VIR stock on Yahoo Finance. View daily, weekly or monthly format back to when Vir Biotechnology, Inc. stock was issued. Vir Biotechnology Inc stock performance at a glance. Check Vir Biotechnology Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. VIR Stock Performance. USD USD; Previous close: 9.49: 9.49: Day range: 9.12 - 9.719.12 - 9.71Year range: 7 - 317 - 31Vir Biotechnology Inc’s stock is NA in 2023, NA in the previous five trading days and down 53.13% in the past year. Currently, Vir Biotechnology Inc does not have a price-earnings ratio. Vir Biotechnology Inc’s trailing 12-month revenue is $490.7 million with a -53.4% net profit margin. As of September 12, 2023, Vir Biotechnology Inc has ...

January 25, 2023 at 08:29 am EST. Vir Biotechnology, Inc. announced that George Scangos, Ph.D., will retire from his position as Chief Executive Officer, effective April 3, 2023. The Company's Board of Directors has appointed industry veteran Marianne De Backer, MSc, Ph.D., MBA, currently Executive Vice President, Head of Pharmaceuticals ...IR Contact. Vir Biotechnology, Inc. 1800 Owens St., Suite 900 San Francisco, CA 94158. contact us by phone 415-906-4324 [email protected]. Follow us. opens in a new windowJun 15, 2023 · Ms. Ramasastry VIR stock SEC Form 4 insiders trading. Saira has made over 11 trades of the Vir Biotechnology Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently she sold 3,500 units of VIR stock worth $89,845 on 1 June 2023.. The largest trade she's ever made was exercising 10,000 units of Vir Biotechnology Inc …Instagram:https://instagram. charles schwab vs ameritradesaga falebllabest brokers for penny stock tradingdivi etf Treatment. Phase: Pre-clinical,100%. 1: MARCH trial (Part B), PREVAIL platform trial (THRIVE/STRIVE sub-protocols) 2: GS-9688. 3: nivolumab. * Per the collaboration agreement announced in February 2021, Vir and GSK are continuing to advance new monoclonal antibody therapeutics for influenza and other respiratory viruses, including RSV. Vir Biotechnology Inc stock performance at a glance. Check Vir Biotechnology Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. us energy stockapy vs dividend rate IR Contact. Vir Biotechnology, Inc. 1800 Owens St., Suite 900 San Francisco, CA 94158. contact us by phone 415-906-4324 [email protected]. Follow us. opens in a new window average cost for hospital stay per day Treatment. Phase: Pre-clinical,100%. 1: MARCH trial (Part B), PREVAIL platform trial (THRIVE/STRIVE sub-protocols) 2: GS-9688. 3: nivolumab. * Per the collaboration agreement announced in February 2021, Vir and GSK are continuing to advance new monoclonal antibody therapeutics for influenza and other respiratory viruses, including RSV. Nov 30, 2023 · Get Vir Biotechnology Inc (VIR.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments